Literature DB >> 26668069

Semiparametric regression for the weighted composite endpoint of recurrent and terminal events.

Lu Mao1, D Y Lin2.   

Abstract

Recurrent event data are commonly encountered in clinical and epidemiological studies. A major complication arises when recurrent events are terminated by death. To assess the overall effects of covariates on the two types of events, we define a weighted composite endpoint as the cumulative number of recurrent and terminal events properly weighted by the relative severity of each event. We propose a semiparametric proportional rates model which specifies that the (possibly time-varying) covariates have multiplicative effects on the rate function of the weighted composite endpoint while leaving the form of the rate function and the dependence among recurrent and terminal events completely unspecified. We construct appropriate estimators for the regression parameters and the cumulative frequency function. We show that the estimators are consistent and asymptotically normal with variances that can be consistently estimated. We also develop graphical and numerical procedures for checking the adequacy of the model. We then demonstrate the usefulness of the proposed methods in simulation studies. Finally, we provide an application to a major cardiovascular clinical trial.
© The Author 2015. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Counting process; Dependent censoring; Intensity function; Inverse probability of censoring weighting; Mean function; Survival analysis

Mesh:

Year:  2015        PMID: 26668069      PMCID: PMC4804115          DOI: 10.1093/biostatistics/kxv050

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  23 in total

1.  Nonparametric analysis of recurrent events and death.

Authors:  D Ghosh; D Y Lin
Journal:  Biometrics       Date:  2000-06       Impact factor: 2.571

2.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

3.  An approach to evaluating thrombolytic therapy in acute myocardial infarction. The 'unsatisfactory outcome' end point.

Authors:  E Braunwald; C P Cannon; C H McCabe
Journal:  Circulation       Date:  1992-08       Impact factor: 29.690

4.  Key issues in end point selection for heart failure trials: composite end points.

Authors:  James D Neaton; Gerry Gray; Bram D Zuckerman; Marvin A Konstam
Journal:  J Card Fail       Date:  2005-10       Impact factor: 5.712

5.  Joint Modeling and Estimation for Recurrent Event Processes and Failure Time Data.

Authors:  Chiung-Yu Huang; Mei-Cheng Wang
Journal:  J Am Stat Assoc       Date:  2004-12       Impact factor: 5.033

6.  Marginal analysis of recurrent events and a terminating event.

Authors:  R J Cook; J F Lawless
Journal:  Stat Med       Date:  1997-04-30       Impact factor: 2.373

Review 7.  Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials.

Authors:  R M Califf; L Harrelson-Woodlief; E J Topol
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

8.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

Authors:  Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

9.  Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial.

Authors:  Inder S Anand; Peter Carson; Elizabeth Galle; Rui Song; John Boehmer; Jalal K Ghali; Brian Jaski; JoAnn Lindenfeld; Christopher O'Connor; Jonathan S Steinberg; Jill Leigh; Patrick Yong; Michael R Kosorok; Arthur M Feldman; David DeMets; Michael R Bristow
Journal:  Circulation       Date:  2009-02-09       Impact factor: 29.690

10.  A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.

Authors:  D I Abrams; A I Goldman; C Launer; J A Korvick; J D Neaton; L R Crane; M Grodesky; S Wakefield; K Muth; S Kornegay
Journal:  N Engl J Med       Date:  1994-03-10       Impact factor: 91.245

View more
  6 in total

1.  Semiparametric temporal process regression of survival-out-of-hospital.

Authors:  Tianyu Zhan; Douglas E Schaubel
Journal:  Lifetime Data Anal       Date:  2018-05-23       Impact factor: 1.588

2.  Modeling marginal features in studies of recurrent events in the presence of a terminal event.

Authors:  Per Kragh Andersen; Jules Angst; Henrik Ravn
Journal:  Lifetime Data Anal       Date:  2019-01-29       Impact factor: 1.588

3.  Statistical models for composite endpoints of death and non-fatal events: a review.

Authors:  Lu Mao; KyungMann Kim
Journal:  Stat Biopharm Res       Date:  2021-07-06       Impact factor: 1.586

4.  On recurrent-event win ratio.

Authors:  Lu Mao; KyungMann Kim; Yi Li
Journal:  Stat Methods Med Res       Date:  2022-03-29       Impact factor: 2.494

5.  Quantifying the totality of treatment effect with multiple event-time observations in the presence of a terminal event from a comparative clinical study.

Authors:  Brian Claggett; Lu Tian; Haoda Fu; Scott D Solomon; Lee-Jen Wei
Journal:  Stat Med       Date:  2018-07-25       Impact factor: 2.373

6.  Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial.

Authors:  Orly Vardeny; KyungMann Kim; Jacob A Udell; Jacob Joseph; Akshay S Desai; Michael E Farkouh; Sheila M Hegde; Adrian F Hernandez; Allison McGeer; H Keipp Talbot; Inder Anand; Deepak L Bhatt; Christopher P Cannon; David DeMets; J Michael Gaziano; Shaun G Goodman; Kristin Nichol; Matthew C Tattersall; Jonathan L Temte; Janet Wittes; Clyde Yancy; Brian Claggett; Yi Chen; Lu Mao; Thomas C Havighurst; Lawton S Cooper; Scott D Solomon
Journal:  JAMA       Date:  2021-01-05       Impact factor: 157.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.